Cardiotoxicity in metastatic melanoma patients treated with BRAF and MEK inhibitors in a real-world setting
Sign Up to like & getrecommendations! Published in 2021 at "Acta Oncologica"
DOI: 10.1080/0284186x.2021.1992010
Abstract: Abstract Background Combination therapy with BRAF and MEK inhibitors (BRAF/MEKi) has significantly improved the outcome for patients with BRAF-mutated melanoma. A reduction in left ventricular ejection fraction (LVEF) is a known side effect during treatment… read more here.
Keywords: mek inhibitors; lvef; braf mek; braf meki ... See more keywords
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
Sign Up to like & getrecommendations! Published in 2022 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2022-004610
Abstract: Background Patients with V600BRAF mutant metastatic melanoma have higher rates of progression-free survival (PFS) and overall survival (OS) with first-line anti-PD1 (PD1]+anti-CTLA-4 (IPI) versus PD1. Whether this is also true after BRAF/MEKi therapy is unknown.… read more here.
Keywords: ipi pd1; melanoma; braf meki; pd1 ipi ... See more keywords
Abstract 6747: Sites of metastases prior to systemic treatment influence progression patterns and survival in stage IV melanoma patients
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-6747
Abstract: Background: Different metastatic sites have distinct response rates to immune checkpoint inhibitors (ICI), suggesting that anatomical locations play a role in treatment response and survival. This project investigated the impact that sites of metastases present… read more here.
Keywords: baseline; sites metastases; progression; braf meki ... See more keywords
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14225694
Abstract: Simple Summary Nodular melanoma is associated with a higher locoregional recurrence rate and worse overall survival outcomes. Whether this histologic subtype affects the efficacy of immunotherapy or targeted therapy is unclear. The aim of our… read more here.
Keywords: survival; braf meki; nodular melanoma; melanoma ... See more keywords